PCRX
Income statement / Annual
Last year (2024), Pacira BioSciences, Inc.'s total revenue was $700.97 M,
an increase of 3.85% from the previous year.
In 2024, Pacira BioSciences, Inc.'s net income was -$99.56 M.
See Pacira BioSciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$700.97 M |
$674.98 M |
$666.82 M |
$541.53 M |
$420.83 M |
$421.03 M |
$337.28 M |
$286.63 M |
$276.37 M |
$249.00 M |
| Cost of Revenue |
$0.00
|
$184.67 M
|
$199.30 M
|
$140.26 M
|
$117.33 M
|
$106.71 M
|
$86.85 M
|
$87.92 M
|
$110.10 M
|
$71.84 M
|
| Gross Profit |
$700.97 M
|
$490.31 M
|
$467.53 M
|
$401.28 M
|
$303.50 M
|
$314.31 M
|
$250.43 M
|
$198.72 M
|
$166.27 M
|
$177.16 M
|
| Gross Profit Ratio |
1
|
0.73
|
0.7
|
0.74
|
0.72
|
0.75
|
0.74
|
0.69
|
0.6
|
0.71
|
| Research and Development Expenses |
$81.58 M
|
$76.26 M
|
$84.80 M
|
$55.55 M
|
$59.42 M
|
$72.12 M
|
$55.69 M
|
$57.29 M
|
$45.68 M
|
$28.66 M
|
| General & Administrative Expenses |
$122.08 M
|
$116.40 M
|
$109.52 M
|
$88.32 M
|
$74.83 M
|
$71.12 M
|
$70.16 M
|
$66.69 M
|
$63.40 M
|
$61.31 M
|
| Selling & Marketing Expenses |
$172.02 M
|
$153.04 M
|
$145.00 M
|
$111.02 M
|
$118.68 M
|
$129.66 M
|
$107.11 M
|
$94.80 M
|
$89.22 M
|
$77.73 M
|
| Selling, General & Administrative Expenses |
$294.10 M
|
$269.44 M
|
$254.52 M
|
$199.35 M
|
$193.52 M
|
$200.78 M
|
$177.27 M
|
$161.49 M
|
$152.61 M
|
$139.04 M
|
| Other Expenses |
$398.66 M
|
$56.94 M
|
$57.29 M
|
$13.55 M
|
$7.87 M
|
$5.70 M
|
-$888,000.00
|
$167,000.00
|
-$82,000.00
|
-$165,000.00
|
| Operating Expenses |
$774.34 M
|
$402.63 M
|
$396.60 M
|
$268.44 M
|
$260.80 M
|
$278.60 M
|
$232.95 M
|
$218.78 M
|
$198.29 M
|
$167.71 M
|
| Cost And Expenses |
$774.34 M
|
$587.30 M
|
$595.90 M
|
$408.70 M
|
$378.13 M
|
$385.32 M
|
$319.80 M
|
$306.70 M
|
$308.40 M
|
$239.54 M
|
| Interest Income |
$19.69 M
|
$11.44 M
|
$4.54 M
|
$896,000.00
|
$4.63 M
|
$7.38 M
|
$6.50 M
|
$4.08 M
|
$1.32 M
|
$678,000.00
|
| Interest Expense |
$13.44 M
|
$20.31 M
|
$39.98 M
|
$31.75 M
|
$25.67 M
|
$23.63 M
|
$21.95 M
|
$18.05 M
|
$7.06 M
|
$7.73 M
|
| Depreciation & Amortization |
$78.79 M
|
$75.57 M
|
$91.50 M
|
$28.55 M
|
$19.91 M
|
$19.58 M
|
$13.17 M
|
$13.83 M
|
$12.92 M
|
$11.48 M
|
| EBITDA |
$29.12 M |
$157.58 M |
$144.78 M |
$118.47 M |
$71.42 M |
$55.29 M |
$33.06 M |
-$10.59 M |
-$17.86 M |
$21.39 M |
| EBITDA Ratio |
0.04
|
0.23
|
0.18
|
0.27
|
0.16
|
0.1
|
0.07
|
-0.06
|
-0.11
|
0.04
|
| Operating Income Ratio |
-0.1
|
0.13
|
0.09
|
0.24
|
0.11
|
0.09
|
0.05
|
-0.09
|
-0.12
|
0.04
|
| Total Other Income/Expenses Net |
$10.27 M
|
-$25.97 M
|
-$46.72 M
|
-$33.52 M
|
-$26.26 M
|
-$26.66 M
|
-$16.34 M
|
-$17.53 M
|
-$5.82 M
|
-$7.34 M
|
| Income Before Tax |
-$63.11 M
|
$61.70 M
|
$13.30 M
|
$56.40 M
|
$20.09 M
|
-$10.75 M
|
-$425,000.00
|
-$42.47 M
|
-$37.84 M
|
$2.12 M
|
| Income Before Tax Ratio |
-0.09
|
0.09
|
0.02
|
0.1
|
0.05
|
-0.03
|
-0
|
-0.15
|
-0.14
|
0.01
|
| Income Tax Expense |
$36.45 M
|
$19.75 M
|
-$2.61 M
|
$14.42 M
|
-$125.43 M
|
$268,000.00
|
$46,000.00
|
$140,000.00
|
$105,000.00
|
$264,000.00
|
| Net Income |
-$99.56 M
|
$41.96 M
|
$15.91 M
|
$41.98 M
|
$145.52 M
|
-$11.02 M
|
-$471,000.00
|
-$42.61 M
|
-$37.95 M
|
$1.86 M
|
| Net Income Ratio |
-0.14
|
0.06
|
0.02
|
0.08
|
0.35
|
-0.03
|
-0
|
-0.15
|
-0.14
|
0.01
|
| EPS |
-2.15 |
0.91 |
0.35 |
0.95 |
3.41 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
0.05 |
| EPS Diluted |
-2.15 |
0.81 |
0.34 |
0.92 |
3.33 |
-0.27 |
-0.0115 |
-1.07 |
-1.02 |
0.04 |
| Weighted Average Shares Out |
$46.25 M
|
$46.22 M
|
$45.52 M
|
$44.26 M
|
$42.67 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.20 M
|
$36.54 M
|
| Weighted Average Shares Out Diluted |
$46.25 M
|
$51.98 M
|
$46.54 M
|
$45.63 M
|
$43.68 M
|
$41.51 M
|
$40.91 M
|
$39.81 M
|
$37.24 M
|
$41.30 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
